ABSTRACT
Genetic and phenotypic traits of children and adolescents with cystic fi brosis in Southern Brazil
Katiana Murieli da Rosa 1,a , Eliandra da Silveira de Lima (1) This gene is located in the long arm of chromosome 7 (locus 7q31), and is divided in 27 exons, generating a protein composed of 1,480 amino acids.
The estimated prevalence in several countries is of 1 for every 2,800-3,500 live births. (2) In Brazil, about 1 out of 10 thousand live births presents with the disorder.
Mutations in CFTR establish a multisystemic aspect for the disease, characterized by pulmonary, gastrointestinal and sweat gland disorders. (4) Life expectancy in patients with CF has been improving, and, nowadays, more than half of them have reached adulthood. (2) Such an improvement, among other factors, is owed to the increment in innovative treatments and the advancement of interdisciplinary care addressed to the patient with CF. (5) Recently, specifi c therapies addressed to the CFTR channel, which are able to correct the basic fl ow, have been developed and approved for use in several countries. These targeted drugs aim at transforming CF therapy, making the prescription of drugs more accurate. (6) Some protocols include genetic evaluation to complement neonatal screening and clinical diagnosis of CF, allowing the identifi cation of patients who are eligible to mutation-specifi c therapies.
The variants identifi ed in CFTR are divided in six classes of mutations, based on their functional effects.
(
The relationship between genotype and the clinical consequences of all variants, however, requires further understanding.
This study aimed at reporting the main CFTR mutations identifi ed in a group of children and adolescents followed-up at a multidisciplinary center for CF treatment in the South of Brazil, and at associating such mutations to specifi c clinical and laboratory characteristics.
METHOD
This is a cross-sectional, descriptive study. Patients who were followed-up at a reference center in the charts. Simultaneously, a literature review was carried out regarding the phenotype described for the most frequent mutations found in our sample.
This study was approved by the Research Ethics
Committee of Pontifícia Universidade Católica do Rio Grande do Sul (PUC-RS) and is registered by n.
49692115.7.0000.5336.
RESULTS
Of the 103 patients with CF followed-up at the multidisciplinary center, 58 (56.3%) have been genotyped. Of these, 42 (72.4%) were included in the study for presenting both known alleles of CFTR. Table 1 contains data referring to the sweat test and age of the patients, and Table 2 shows Among the patients who presented with alterations for p.Phe.508del, 57.89% were homozygous for the mutation. The second most common mutation was class I, with mutation G542X (p.Gly542X), present in six alleles (7.14%), followed by the mutations N1303K (p.Asn1303Lys) and R1162X (p.Arg1162X), also class I, in four alleles (4.76%) each.
Of the 42 patients analyzed, 11 (26.2%) had meconium ileus, in which the following mutations were identifi ed: F508del, G542X and R1162X. All of these represented mutation F508del, and seven patients (63.6%) were homozygous for this mutation. Three patients (27.3%) pointed mutation G542X as the second allele, and one patient showed mutation R1162X.
Regarding nutritional status, seven patients (16.7%)
had defi cit, characterized by BMI being below the lower limit of normal before or after the condition was diagnosed, and in these cases the following mutations were identifi ed: F508del, R1162X e R347X;
all of them contained mutation F508del. Of these, four were homozygous for F508del, two presented R1162X, and one, mutation R347X. 
DISCUSSION
Genotype-phenotype associations in CF, modifi er genes, epigenetic factors, and environmental infl uence help to understand the broad spectrum of disease manifestations, which can range between single to multisystemic involvement, and between mild to severe disease. (8) In this sample of patients with CF, F508deI was the most common mutation, affecting more than 50% of the homozygous individuals. This class II mutation, responsible for the incorrect processing of the CFTR protein, present in approximately 70% of the Caucasian population with CF (9) , is considered as a severe mutation, showing the classic phenotype of the disease. Individuals who are homozygous for this mutation usually present with high sweat chloride test results (mean of 98 mEq/L), early signs of respiratory symptoms, reduced pulmonary function, pancreatic insuffi ciency and delayed growth (10) . It is the most known and studied mutation that causes CF.
Three other mutations were observed often in our sample: G542X, R1162X and N1303K. Mutation G542X
(class I), characterized by a change that results in the absence of the CFTR protein, was the second most prevalent in this sample of patients (six alleles, 7.14%), and its frequency is estimated between 2.7 and 8.5% in Brazil. (11, 12) This mutation is responsible for the high incidence of meconium ileus. (13) among the most common ones (10) for patients with CF, whose frequency is higher than 1%, and shows great variation between countries and ethnicities. (15) (16) (17) Considered as a severe mutation, its phenotype is related to severe pancreatic consequences, and may lead to pancreatic insuffi ciency and diabetes mellitus. (15, 16, 18) Regarding pulmonary phenotype, the severity of the disease indicates great variability between the different mutations. (15, 18) In this sample, patients identifi ed with mutation N1303K in one of the alleles had pancreatic insuffi ciency.
The other mutations that were found, being each of them presented in one patient, were revised next.
Mutation 3132del TG (class I) is rare, and ongoing population studies (10) will help to determine its disease phenotype. Mutation 711+5G>A (class I) is more common among Hispanic Americans and in Northeast
Italy. A study that included two patients with this mutation associated with F508del showed that these patients had chronic colonization by PA and SA, liver disease and pancreatitis more often. (19) The class III G551D mutation, which is related to the obstruction of the chloride passage through the 
Of the patients with CF, 0.7% have at least one copy of the G85E mutation (class II). (20, 21) Patients with genotype G85E/F508del are similar to the ones homozygous for F508del, when it comes to mean age of diagnosis, mean values of chloride in the sweat, weight/height ratio, spirometry (FEV1), and colonization by PA. 
Mutation R1066C (class II) represents 5% of mutations for CF in Portugal, and 1% in Spain, places where a study assessed 28 patients with this mutation.
It is a severe mutation, similar to that observed in patients homozygous for F508del. (26) The presence of mutation D1152H (class IV), In conclusion, the mutations more often identifi ed were F508del and G542X, which have higher severity profi les. In our sample, 22 patients (52.38%) would be potential candidates for the use of the compound Lumacaftor-Ivacaftor, which has proven to be effective in subjects aged more than 6 years homozygous for the F508del mutation. Besides, three patients (7.14%)
would be candidates for the use of Ivacaftor, drug that can be used in individuals who present with 33
class III or IV mutations, such as G551D, R347H and 1152H, which were present in these patients.
